Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Eukaryotic Evolution01:24

Eukaryotic Evolution

29.8K
The endosymbiont theory is the most widely accepted theory of eukaryotic evolution; however, its progression is still somewhat debated. According to the nucleus-first hypothesis, the ancestral prokaryote first evolved a membrane to enclose DNA and form the nucleus. Conversely, the mitochondria-first hypothesis suggests that the nucleus was formed after endosymbiosis of mitochondria.
Contrary to the endosymbiont theory, the eukaryote-first hypothesis proposes that the simpler prokaryotic and...
29.8K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

13.6K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
13.6K
The Eukaryotic Promoter Region02:40

The Eukaryotic Promoter Region

2.8K
2.8K
Maintenance of the ES Cell State01:14

Maintenance of the ES Cell State

2.1K
The cells of the blastocyst inner cell mass only remain pluripotent for a short time. This state of pluripotency and self-renewal can be maintained in embryonic stem (ES) cell culture by adding specific chemicals or growth factors to ensure the cells can continue dividing and later differentiate into different cell types. In some cases, the cells are grown on a feeder layer of differentiated cells, which provides the growth factors and extracellular matrix components necessary for stem cell...
2.1K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K
Eukaryotic Transcription Activators02:42

Eukaryotic Transcription Activators

10.7K
Transcription activators are proteins that promote the transcription of genes from DNA to RNA. In most cases, these proteins contain two separate domains ‒ a domain that binds to DNA and a domain for activating transcription; however, in some cases, a single domain is responsible for both binding and activation of transcription, as seen in the glucocorticoid receptor and MyoD.
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

British journal of haematology·2026
Same author

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Blood advances·2026
Same author

Pathological and molecular characterization of a four-component combined small cell lung carcinoma: a case report.

Translational lung cancer research·2026
Same author

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Blood advances·2026
Same author

Feasibility study of photoimmunotherapy combination with ASP-1929 for vulvar, vaginal, and cervical cancer.

Journal of gynecologic oncology·2026
Same author

Hokkaido phase II study of photo-immunotherapy combination with ASP-1929 for recurrent or persistent EGFR-positive vulvar, vaginal, and cervical cancers not amenable to further radiotherapy (HICARi study).

Journal of gynecologic oncology·2026

Related Experiment Video

Updated: May 12, 2025

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
21:55

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling

Published on: April 2, 2012

28.3K

Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells.

Masahide Osaki1, Seitaro Terakura2, Shiho Hirano1

  • 1Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Journal for Immunotherapy of Cancer
|May 9, 2025
PubMed
Summary

Chimeric antigen receptor T (CAR-T) cell therapy targeting Epithelial V-like antigen 1 (Eva1) shows promise for solid tumors. Optimized Eva1CAR-T cells demonstrated significant efficacy in preclinical models, suggesting potential for treating various Eva1-positive solid cancers.

Keywords:
Adoptive cell therapy - ACTChimeric antigen receptor - CARLung CancerSolid tumor

More Related Videos

A Modeling and Simulation Method for Preliminary Design of an Electro-Variable Displacement Pump
09:04

A Modeling and Simulation Method for Preliminary Design of an Electro-Variable Displacement Pump

Published on: June 1, 2022

3.0K
Optimizing Extracellular Vesicle Delivery Using a Core-Sheath 3D-Bioprinted Scaffold for Chronic Wound Management
09:23

Optimizing Extracellular Vesicle Delivery Using a Core-Sheath 3D-Bioprinted Scaffold for Chronic Wound Management

Published on: February 28, 2025

159

Related Experiment Videos

Last Updated: May 12, 2025

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
21:55

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling

Published on: April 2, 2012

28.3K
A Modeling and Simulation Method for Preliminary Design of an Electro-Variable Displacement Pump
09:04

A Modeling and Simulation Method for Preliminary Design of an Electro-Variable Displacement Pump

Published on: June 1, 2022

3.0K
Optimizing Extracellular Vesicle Delivery Using a Core-Sheath 3D-Bioprinted Scaffold for Chronic Wound Management
09:23

Optimizing Extracellular Vesicle Delivery Using a Core-Sheath 3D-Bioprinted Scaffold for Chronic Wound Management

Published on: February 28, 2025

159

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Engineering

Background:

  • Chimeric antigen receptor T (CAR-T) cell therapy is established for hematologic malignancies but not solid tumors.
  • Epithelial V-like antigen 1 (Eva1), a surface protein on various tumor cells, is a potential target for solid tumor therapy.

Purpose of the Study:

  • To develop and optimize CAR-T cells targeting Epithelial V-like antigen 1 (Eva1) for solid tumors.
  • To evaluate the efficacy and safety of Eva1-targeted CAR-T cells in preclinical models.

Main Methods:

  • Humanized single-chain variable fragment sequences were generated against Eva1.
  • Six humanized Eva1CAR-T cell constructs were created and optimized for specificity and proliferation.
  • In vitro and in vivo xenograft mouse models were used to assess therapeutic efficacy and cytokine release.

Main Results:

  • Eva1 expression was confirmed on various tumor cell lines, with weak expression on normal monocytes.
  • Optimized Eva1CAR-T cells with short spacer domains and specific intracellular domains showed enhanced efficacy.
  • A single dose of humanized Eva1CAR-T cells demonstrated significant therapeutic effects in lung and pancreatic cancer models.

Conclusions:

  • Humanized Eva1CAR-T cells exhibit promising therapeutic potential for Eva1-positive solid tumors.
  • Further investigation into on-target/off-tumor effects on normal tissues is warranted.